Dublin, 21 September, 2010: Biosensia, the Ireland based Point-of-Care in vitro diagnostics company today announced that CEO Jim Walsh will present at the Enterprise Ireland Investor Forum in London on November 2nd, 2010, at 9:30 a.m.
This full-day London Investor Forum, hosted by Enterprise Ireland, offers investors the opportunity to evaluate over 20 investment opportunities in companies in the Software and Life Sciences sectors.
LONDON INVESTOR FORUM
|Date:||Tuesday 2nd November, 2010|
|Venue:||The Hilton London Tower Bridge Hotel|
Jim Walsh, CEO of Biosensia will introduce forum attendees to Biosensia’s lead product – a highly innovative, practical and cost-effective point of care platform ‘RapiPlex’. The technology is available for applications in diverse global diagnostic markets for human and veterinary assays, food safety, and environmental testing.
According to Diarmuid Flavin, COO of Biosensia the company is delighted to be attending the Enterprise Ireland Investor Forum. “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications. Our presence at the Investor Forum is a great opportunity for Biosensia as it will afford investors in the UK, and indeed further a field the opportunity to learn more about our company, our technology, and the solutions we offer”.
Investors who would like a private meeting with Biosensia representatives at the forum should contact Diarmuid Flavin at info @ biosensia.com or tel.+353 1 7163650
To find out more about the London Investor Forum being organised by Enterprise Ireland see http://www.enterprise-ireland.com/en/Events/OurEvents/Investor-Forum-2010
Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics. Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications. With RapiPlex, Biosensia is primed to expand the capabilities of in-vitro diagnostic technologies by balancing innovation which improves turnaround times, specificity and sensitivity with the need to produce cost-effective, user friendly systems.